{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:19:55Z","timestamp":1794359995097,"version":"4.9.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Recent data have shown a decreasing overall mortality in acromegaly over the last decades. However, cancer incidence and cancer-related mortality still appear to be increased. Our aim was to obtain updated epidemiological data from Norway in a clinically well-defined cohort with complete register-based follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients diagnosed with acromegaly from South-Eastern Norway between 1999\u20132019 (<jats:italic>n<\/jats:italic>\u2009=\u2009262) and age and sex matched population controls (1:100) were included (<jats:italic>n<\/jats:italic>\u2009=\u200926,200). Mortality and cancer data were obtained from the Norwegian Cause of Death and Cancer Registry. Mortality and cancer incidence were compared by Kaplan\u2013Meier analyses and Cox regression; we report hazard ratios (HRs) with 95% confidence intervals (95% CI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median age at diagnosis was 48.0 years (interquartile range (IQR): 37.6\u201358.0). Mean annual acromegaly incidence rate was 4.7 (95% CI 4.2\u20135.3) cases\/10<jats:sup>6<\/jats:sup> person-years, and the point prevalence (2019) was 83 (95% CI 72.6\u201393.5) cases\/10<jats:sup>6<\/jats:sup> persons. Overall mortality was not increased in acromegaly, HR 0.8 (95% CI 0.5\u20131.4), cancer-specific and cardiovascular-specific mortality was also not increased (HR: 0.7 (95% CI 0.3\u20131.8) and 0.8 (95% CI: 0.3\u20132.5) respectively). The HR for all cancers was 1.45 (1.0\u20132.1; <jats:italic>p<\/jats:italic>\u2009=\u20090.052).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this large cohort study, covering the period 1999\u20132019, patients were treated with individualized multimodal management. Mortality was not increased compared to the general population and comparable with recent registry studies from the Nordic countries and Europe. Overall cancer risk was slightly, but not significantly increased in the patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-022-03275-6","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T08:03:55Z","timestamp":1671177835000},"page":"152-159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Trends in incidence and mortality risk for acromegaly in Norway: a cohort study"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9894-5245","authenticated-orcid":false,"given":"Camilla M.","family":"Falch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoleta C.","family":"Olarescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bollerslev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf M.","family":"Dekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"issue":"9","key":"3275_CR1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"S. Melmed, M.D. Bronstein, P. Chanson, A. Klibanski, F.F. Casanueva, J.A.H. Wass et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14(9), 552\u201361. (2018)","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"3275_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-18-0255","volume":"179","author":"F Bolfi","year":"2018","unstructured":"F. Bolfi, A.F. Neves, C.L. Boguszewski, V.S. Nunes-Nogueira, Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur. J. Endocrinol. 179(1), 59\u201371 (2018)","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"3275_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1530\/EJE-18-0015","volume":"178","author":"D Esposito","year":"2018","unstructured":"D. Esposito, O. Ragnarsson, D. Granfeldt, T. Marlow, G. Johannsson, D.S. Olsson, Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. Eur. J. Endocrinol. 178(5), 459\u201369. (2018)","journal-title":"Eur. J. Endocrinol."},{"issue":"8","key":"3275_CR4","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1210\/jc.2008-0315","volume":"93","author":"SM Carlsen","year":"2008","unstructured":"S.M. Carlsen, M. Lund-Johansen, T. Schreiner, S. Aanderud, O. Johannesen, J. Svartberg et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J. Clin. Endocrinol. Metab. 93(8), 2984\u20132990 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"3275_CR5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/cen.14828","volume":"97","author":"C Aagaard","year":"2022","unstructured":"C. Aagaard, A.S. Christophersen, S. Finnerup, C. Rosendal, H.A. Gulisano, K.S. Ettrup, et al. The prevalence of acromegaly is higher than previously reported: changes over a three-decade period. Clin. Endocrinol. 97(6), 773\u2013782 (2022)","journal-title":"Clin. Endocrinol"},{"issue":"9","key":"3275_CR6","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1210\/clinem\/dgac400","volume":"107","author":"D Esposito","year":"2022","unstructured":"D. Esposito, D.S. Olsson, S. Franz\u00e9n, M. Miftaraj, J. N\u00e5tman, S. Gudbj\u00f6rnsdottir et al. Effect of diabetes on morbidity and mortality in patients with acromegaly. J. Clin. Endocrinol. Metab. 107(9), 2483\u201392. (2022)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9418","key":"3275_CR7","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/S0140-6736(04)16044-3","volume":"363","author":"AG Renehan","year":"2004","unstructured":"A.G. Renehan, M. Zwahlen, C. Minder, S.T. O\u2019Dwyer, S.M. Shalet, M. Egger, Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418), 1346\u20131353 (2004)","journal-title":"Lancet"},{"issue":"23","key":"3275_CR8","doi-asserted-by":"publisher","first-page":"E3250","DOI":"10.1073\/pnas.1600561113","volume":"113","author":"V Chesnokova","year":"2016","unstructured":"V. Chesnokova, S. Zonis, C. Zhou, M.V. Recouvreux, A. Ben-Shlomo, T. Araki et al. Growth hormone is permissive for neoplastic colon growth. Proc. Natl Acad. Sci. USA 113(23), E3250\u2013E3259 (2016)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3275_CR9","doi-asserted-by":"publisher","first-page":"924952","DOI":"10.3389\/fendo.2022.924952","volume":"13","author":"L Kasuki","year":"2022","unstructured":"L. Kasuki, B. Maia, M.R. Gadelha, Acromegaly and colorectal neoplasm: an update. Front Endocrinol. 13, 924952 (2022)","journal-title":"Front Endocrinol."},{"issue":"2","key":"3275_CR10","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1530\/EJE-19-0124","volume":"181","author":"J Bollerslev","year":"2019","unstructured":"J. Bollerslev, A. Heck, N.C. Olarescu, Management of endocrine disease: individualised management of acromegaly. Eur. J. Endocrinol. 181(2), R57\u2013r71 (2019)","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"3275_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-07-0358","volume":"157","author":"M Bex","year":"2007","unstructured":"M. Bex, R. Abs, G. T\u2019Sjoen, J. Mockel, B. Velkeniers, K. Muermans et al. AcroBel\u2013the Belgian registry on acromegaly: a survey of the \u2018real-life\u2019 outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157(4), 399\u2013409 (2007)","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"3275_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1517\/13543780802554357","volume":"18","author":"J Bollerslev","year":"2009","unstructured":"J. Bollerslev, S.L. Fougner, J.P. Berg, New directions in pharmacological treatment of acromegaly. Expert Opin. Investigational drugs 18(1), 13\u201322 (2009)","journal-title":"Expert Opin. Investigational drugs"},{"issue":"6","key":"3275_CR13","first-page":"668","volume":"21","author":"M Fleseriu","year":"2015","unstructured":"M. Fleseriu, A.R. Hoffman, L. Katznelson, American Association of Clinical Endocrinologists and American College of Endocrinology Disease State clinical review: management of acromegaly patients: what is the role of pre-operative medical therapy? Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinologists 21(6), 668\u2013673 (2015)","journal-title":"Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinologists"},{"issue":"7","key":"3275_CR14","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141\u20133148 (2010)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"3275_CR15","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"L. Katznelson, E.R. Laws Jr., S. Melmed, M.E. Molitch, M.H. Murad, A. Utz et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933\u20133951 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"3275_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s12020-015-0853-x","volume":"52","author":"M Losa","year":"2016","unstructured":"M. Losa, J. Bollerslev, Pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly. Endocrine 52(3), 451\u2013457 (2016)","journal-title":"Endocrine"},{"issue":"6","key":"3275_CR17","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/j.1365-2265.2011.03982.x","volume":"74","author":"SM Carlsen","year":"2011","unstructured":"S.M. Carlsen, J. Svartberg, T. Schreiner, S. Aanderud, O. Johannesen, S. Skeie et al. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin. Endocrinol. 74(6), 736\u2013743 (2011)","journal-title":"Clin. Endocrinol."},{"issue":"2","key":"3275_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1530\/EJE-14-0249","volume":"171","author":"SL Fougner","year":"2014","unstructured":"S.L. Fougner, J. Bollerslev, J. Svartberg, M. Oksnes, J. Cooper, S.M. Carlsen, Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. Eur. J. Endocrinol. 171(2), 229\u2013235 (2014)","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"3275_CR19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11102-014-0602-9","volume":"18","author":"VS Nunes","year":"2015","unstructured":"V.S. Nunes, J.M. Correa, M.E. Puga, E.M. Silva, C.L. Boguszewski, Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system. Pituitary 18(4), 500\u2013508 (2015)","journal-title":"Pituitary"},{"issue":"1","key":"3275_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1210\/jc.2007-1191","volume":"93","author":"OM Dekkers","year":"2008","unstructured":"O.M. Dekkers, N.R. Biermasz, A.M. Pereira, J.A. Romijn, J.P. Vandenbroucke, Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab. 93(1), 61\u201367 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"3275_CR21","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1210\/jc.2017-02457","volume":"103","author":"J Dal","year":"2018","unstructured":"J. Dal, M.Z. Leisner, K. Hermansen, D.K. Farkas, M. Bengtsen, C. Kistorp et al. Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature. J. Clin. Endocrinol. Metab. 103(6), 2182\u20132188 (2018)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"3275_CR22","first-page":"2730","volume":"83","author":"SM Orme","year":"1998","unstructured":"S.M. Orme, R.J. McNally, R.A. Cartwright, P.E. Belchetz, Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J. Clin. Endocrinol. Metab. 83(8), 2730\u20132734 (1998)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"3275_CR23","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1210\/jc.2015-2372","volume":"100","author":"D Petroff","year":"2015","unstructured":"D. Petroff, A. T\u00f6njes, M. Grussendorf, M. Droste, C. Dimopoulou, G. Stalla et al. The incidence of cancer among acromegaly patients: results from the German Acromegaly Registry. J. Clin. Endocrinol. Metab. 100(10), 3894\u20133902 (2015)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3-4","key":"3275_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000371818","volume":"103","author":"NC Olarescu","year":"2016","unstructured":"N.C. Olarescu, A. Heck, K. Godang, T. Ueland, J. Bollerslev, The metabolic risk in patients newly diagnosed with acromegaly is related to fat distribution and circulating adipokines and improves after treatment. Neuroendocrinology 103(3-4), 197\u2013206 (2016)","journal-title":"Neuroendocrinology"},{"key":"3275_CR25","doi-asserted-by":"crossref","unstructured":"Working Group Report. International rules for multiple primary cancers (ICD-0 third edition). Eur. J. Cancer Prev. 14(4), 307\u2013308 (2016)","DOI":"10.1097\/00008469-200508000-00002"},{"issue":"3","key":"3275_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/EJE-16-0117","volume":"175","author":"J Dal","year":"2016","unstructured":"J. Dal, U. Feldt-Rasmussen, M. Andersen, L.O. Kristensen, P. Laurberg, L. Pedersen et al. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur. J. Endocrinol. 175(3), 181\u2013190 (2016)","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"3275_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1530\/EJE-14-0144","volume":"171","author":"A Tjornstrand","year":"2014","unstructured":"A. Tjornstrand, K. Gunnarsson, M. Evert, E. Holmberg, O. Ragnarsson, T. Rosen et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur. J. Endocrinol. 171(4), 519\u2013526 (2014)","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"3275_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1530\/EJE-15-0189","volume":"173","author":"TT Agustsson","year":"2015","unstructured":"T.T. Agustsson, T. Baldvinsdottir, J.G. Jonasson, E. Olafsdottir, V. Steinthorsdottir, G. Sigurdsson et al. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur. J. Endocrinol. 173(5), 655\u2013664 (2015)","journal-title":"Eur. J. Endocrinol."},{"issue":"7","key":"3275_CR29","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1210\/jc.2004-1381","volume":"90","author":"R Kauppinen-M\u00e4kelin","year":"2005","unstructured":"R. Kauppinen-M\u00e4kelin, T. Sane, A. Reunanen, M.J. V\u00e4lim\u00e4ki, L. Niskanen, H. Markkanen et al. A nationwide survey of mortality in acromegaly. J. Clin. Endocrinol. Metab. 90(7), 4081\u20134086 (2005)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"3275_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1530\/EJE-21-0729","volume":"186","author":"S Arnard\u00f3ttir","year":"2022","unstructured":"S. Arnard\u00f3ttir, J. J\u00e4r\u00e5s, P. Burman, K. Berinder, P. Dahlqvist, E.M. Erfurth et al. Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register. Eur. J. Endocrinol. 186(3), 329\u201339. (2022)","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"3275_CR31","doi-asserted-by":"publisher","first-page":"X1","DOI":"10.1530\/EJE-18-0015e","volume":"180","author":"D Esposito","year":"2019","unstructured":"D. Esposito, O. Ragnarsson, D. Granfeldt, T. Marlow, G. Johannsson, D.S. Olsson, Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. Eur. J. Endocrinol. 180(2), X1\u2013X3 (2019)","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"3275_CR32","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1530\/EJE-20-1124","volume":"184","author":"OM Dekkers","year":"2021","unstructured":"O.M. Dekkers, R.H.H. Groenwold, When observational studies can give wrong answers: the potential of immortal time bias. Eur. J. Endocrinol. 184(1), E1\u2013e4 (2021)","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"3275_CR33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/cen.14392","volume":"94","author":"J Dal","year":"2021","unstructured":"J. Dal, B.G. Skov, M. Andersen, U. Feldt-Rasmussen, C.L. Feltoft, J. Karmisholt et al. Sex differences in acromegaly at diagnosis: a nationwide cohort study and meta-analysis of the literature. Clin. Endocrinol. 94(4), 625\u201335. (2021)","journal-title":"Clin. Endocrinol."},{"issue":"5","key":"3275_CR34","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1530\/EJE-19-1023","volume":"182","author":"NF Lenders","year":"2020","unstructured":"N.F. Lenders, A.I. McCormack, K.K.Y. Ho, Management of endocrine disease: does gender matter in the management of acromegaly? Eur. J. Endocrinol. 182(5), R67\u2013r82 (2020)","journal-title":"Eur. J. Endocrinol."},{"issue":"12","key":"3275_CR35","first-page":"3487","volume":"106","author":"D Esposito","year":"2021","unstructured":"D. Esposito, O. Ragnarsson, G. Johannsson, D.S. Olsson, Incidence of benign and malignant tumors in patients with acromegaly is increased: a nationwide population-based study. J. Clin. Endocrinol. Metabol. 106(12), 3487\u20133496 (2021)","journal-title":"J. Clin. Endocrinol. Metabol"},{"issue":"9","key":"3275_CR36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1530\/ERC-16-0553","volume":"24","author":"M Terzolo","year":"2017","unstructured":"M. Terzolo, G. Reimondo, P. Berchialla, E. Ferrante, E. Malchiodi, L. De Marinis et al. Acromegaly is associated with increased cancer risk: a survey in Italy. Endocr. Relat. Cancer 24(9), 495\u2013504 (2017)","journal-title":"Endocr. Relat. Cancer"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03275-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03275-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03275-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T11:35:50Z","timestamp":1680089750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03275-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["3275"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03275-6","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"assertion":[{"value":"31 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A.H. has received speaker fees from Recordati and Ipsen. J.B. has received speaker fees from Ipsen and Pfizer, and has served as an advisory board member for Pfizer. N.C.O. received speaker fees from CORE2ED (supported by a medical education grant from Ipsen). O.M.D. and C.M.F. have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the regional ethics committee (REK no: 15240) and the hospital authority.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}